aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitisRong Fan, Jinlin Hou, Xiaoguang Dou et al.|Journal of Hepatology|2020Cited by 346
Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: an individual patient data meta-analysisVíctor Sapena, María Reig, Marco Enea et al.|Gut|2021Cited by 96
Safety and efficacy of dual direct-acting antiviral therapy (daclatasvir and asunaprevir) for chronic hepatitis C virus genotype 1 infection in patients on hemodialysisHidenori Toyoda, Yasuhito Tanaka, Takashi Kumada et al.|Journal of Gastroenterology|2016Cited by 76
Erratum to: Safety and efficacy of dual direct-acting antiviral therapy (daclatasvir and asunaprevir) for chronic hepatitis C virus genotype 1 infection in patients on hemodialysisHidenori Toyoda, Yasuhito Tanaka, Takashi Kumada et al.|Journal of Gastroenterology|2016Cited by 60
Quantitative measurements of M2BPGi depend on liver fibrosis and inflammationHaruki Uojima, Masashi Mizokami, Kazumi Yamasaki et al.|Journal of Gastroenterology|2024Cited by 23